FDA-Issued CRL for Relacorilant NDA Leads to Bullish Views Around Corcept Therapeutics (CORT)

Corcept Therapeutics (NASDAQ:CORT) is 1 of the 17 biotechnology stocks with much than 50% upside.

On February 2, Edward Nash from Canaccord Genuity reaffirmed his Buy standing for Corcept Therapeutics (NASDAQ:CORT). He forecasted a terms people of $100, which leads to astir 161% upside imaginable connected the stock.

Nestor Rizhniak/Shutterstock.com

Nash noted that the CRL issued by the U.S. FDA for the relacorilant NDA confirms their anterior expectations. Their exemplary already accounted for the request to behaviour an further trial, starring them to origin successful a three-year hold for relacorilant to participate the Cushing’s market.

On January 22, the terms people connected Corcept Therapeutics (NASDAQ:CORT) was raised from $90 to $105 by H.C. Wainwright expert Swayampakula Ramakanth. He maintained his Buy standing connected the stock, which helium expects has an upside imaginable of astir 174%.

Based connected awesome endurance data, Ramakanth raised his marketplace penetration forecast for relacorilant successful ovarian cancer, moving it from 20% to 25%. The institution precocious shared palmy median results for endurance information from its large Phase 3 ROSELLA study, which focuses connected platinum-resistant ovarian cancer.

Corcept Therapeutics (NASDAQ:CORT) is simply a commercial-stage pharmaceutical institution processing therapies for terrible conditions. These see endocrinologic, oncologic, metabolic, and neurologic disorders. It is processing medicines that people hyperglycemia, hypercortisolism, prostate cancer, and amyotrophic lateral sclerosis.

While we admit the imaginable of CORT arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 15 Most Promising Mid-Cap Healthcare Stocks Under $50 and 11 Most Promising Small-Cap Industrial Stocks Under $50.

Disclosure: None. This nonfiction is primitively published astatine Insider Monkey.